Connection

PARTOW KEBRIAEI to Child

This is a "connection" page, showing publications PARTOW KEBRIAEI has written about Child.
Connection Strength

0.433
  1. Hematopoietic cell transplantation for acute lymphoblastic leukemia: review of current indications and outcomes. Leuk Lymphoma. 2021 12; 62(12):2831-2844.
    View in: PubMed
    Score: 0.042
  2. Debate: Transplant Is Still Necessary in the Era of Targeted Cellular Therapy for Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2020 11; 20(11):713-719.
    View in: PubMed
    Score: 0.040
  3. A Phase 3 Randomized Study of Remestemcel-L versus Placebo Added to Second-Line Therapy in Patients with Steroid-Refractory Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2020 05; 26(5):835-844.
    View in: PubMed
    Score: 0.038
  4. Multi-center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes. Bone Marrow Transplant. 2017 Jan; 52(1):20-27.
    View in: PubMed
    Score: 0.031
  5. Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):296-301.
    View in: PubMed
    Score: 0.024
  6. Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia. Bone Marrow Transplant. 2013 May; 48(5):666-70.
    View in: PubMed
    Score: 0.023
  7. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes. Biol Blood Marrow Transplant. 2012 Apr; 18(4):584-92.
    View in: PubMed
    Score: 0.022
  8. Characteristics and outcomes of children, adolescents and young adults with relapsed/refractory non-hodgkin lymphoma undergoing autologous stem cell transplant. BMC Cancer. 2023 Dec 20; 23(1):1258.
    View in: PubMed
    Score: 0.013
  9. Umbilical Cord Blood Transplantation: Connecting Its Origin to Its Future. Stem Cells Transl Med. 2023 03 03; 12(2):55-71.
    View in: PubMed
    Score: 0.012
  10. HLA Factors versus Non-HLA Factors for Haploidentical Donor Selection. Transplant Cell Ther. 2023 03; 29(3):189-198.
    View in: PubMed
    Score: 0.012
  11. Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. Nat Rev Clin Oncol. 2021 07; 18(7):435-453.
    View in: PubMed
    Score: 0.010
  12. Patient-Reported Outcomes for Cancer Patients with Hematological Malignancies Undergoing Chimeric Antigen Receptor T Cell Therapy: A Systematic Review. Transplant Cell Ther. 2021 05; 27(5):390.e1-390.e7.
    View in: PubMed
    Score: 0.010
  13. Improved detection of sinusoidal obstructive syndrome using pediatric-AYA diagnostic criteria and severity grading. Bone Marrow Transplant. 2021 01; 56(1):175-184.
    View in: PubMed
    Score: 0.010
  14. Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement. Lancet Haematol. 2020 Jan; 7(1):e61-e72.
    View in: PubMed
    Score: 0.010
  15. Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nat Rev Clin Oncol. 2019 01; 16(1):45-63.
    View in: PubMed
    Score: 0.009
  16. Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019 03; 25(3):e76-e85.
    View in: PubMed
    Score: 0.009
  17. Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. Lancet Haematol. 2018 Nov; 5(11):e532-e542.
    View in: PubMed
    Score: 0.009
  18. Is a matched unrelated donor search needed for all allogeneic transplant candidates? Blood Adv. 2018 09 11; 2(17):2254-2261.
    View in: PubMed
    Score: 0.009
  19. Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit. Bone Marrow Transplant. 2018 03; 53(3):315-325.
    View in: PubMed
    Score: 0.008
  20. Histologic Grade 1 Is Associated With Increased Nonrelapsed Mortality in Lower Gastrointestinal Graft Versus Host Disease. Am J Surg Pathol. 2017 Nov; 41(11):1483-1490.
    View in: PubMed
    Score: 0.008
  21. Etiologies and Impact of Readmission Rates in the First 180 Days After Hematopoietic Stem Cell Transplantation in Children, Adolescents, and Young Adults. J Pediatr Hematol Oncol. 2017 11; 39(8):609-613.
    View in: PubMed
    Score: 0.008
  22. A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results. Br J Haematol. 2017 08; 178(4):561-570.
    View in: PubMed
    Score: 0.008
  23. Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Leukemia. 2017 07; 31(7):1654-1657.
    View in: PubMed
    Score: 0.008
  24. Long-Term Outcomes after Treatment with Clofarabine???Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant. 2016 10; 22(10):1792-1800.
    View in: PubMed
    Score: 0.008
  25. Better allele-level matching improves transplant-related mortality after double cord blood transplantation. Haematologica. 2015 Oct; 100(10):1361-70.
    View in: PubMed
    Score: 0.007
  26. Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies. Biol Blood Marrow Transplant. 2015 May; 21(5):906-12.
    View in: PubMed
    Score: 0.007
  27. Low rate of infusional toxicity after expanded cord blood transplantation. Cytotherapy. 2014 Aug; 16(8):1153-7.
    View in: PubMed
    Score: 0.006
  28. The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation. Clin Lymphoma Myeloma Leuk. 2014 Feb; 14(1):e1-5.
    View in: PubMed
    Score: 0.006
  29. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013 Aug 01; 119(15):2728-36.
    View in: PubMed
    Score: 0.006
  30. Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation. Br J Haematol. 2013 Mar; 160(6):798-805.
    View in: PubMed
    Score: 0.006
  31. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012 Apr; 13(4):403-11.
    View in: PubMed
    Score: 0.006
  32. Platelet recovery before allogeneic stem cell transplantation predicts posttransplantation outcomes in patients with acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2011 Dec; 17(12):1841-5.
    View in: PubMed
    Score: 0.005
  33. Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. Bone Marrow Transplant. 2010 Mar; 45(3):429-36.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.